Therapeutic application of mesenchymal stem cells in osteoarthritis

Ruiz, Maxime; Cosenza, Stella; Maumus, Marie; Jørgensen, Christian; Noël, Danièle

doi:10.1517/14712598.2016.1093108

Cited by 74 publications

(57 citation statements)

References 87 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the collagenase-induced murine model of OA (CIOA), a single intra-articular injection of ASCs at early-stage inhibited synovial thickening and cartilage destruction likely by inhibiting synovial macrophage activation [42]. Since then, several studies confirmed benefit of local injection of MSCs in different models, including rabbit, dog and goats [43,44,45]. Interestingly, addition of platelet-rich-plasma (PRP) enhanced the therapeutic efficacy of co-injected MSCs [46,47].…”

Section: Mesenchymal Stem Cells and Rheumatic Diseasesmentioning

confidence: 99%

Pathogenic or Therapeutic Extracellular Vesicles in Rheumatic Diseases: Role of Mesenchymal Stem Cell-Derived Vesicles

Cosenza

Ruiz

Maumus

et al. 2017

IJMS

Self Cite

View full text Add to dashboard Cite

Extracellular vesicles (EVs) are important mediators of cell-to-cell communication pathways via the transport of proteins, mRNA, miRNA and lipids. There are three main types of EVs, exosomes, microparticles and apoptotic bodies, which are classified according to their size and biogenesis. EVs are secreted by all cell types and their function reproduces that of the parental cell. They are involved in many biological processes that regulate tissue homeostasis and physiopathology of diseases. In rheumatic diseases, namely osteoarthritis (OA) and rheumatoid arthritis (RA), EVs have been isolated from synovial fluid and shown to play pathogenic roles contributing to progression of both diseases. By contrast, EVs may have therapeutic effect via the delivery of molecules that may stop disease evolution. In particular, EVs derived from mesenchymal stem cells (MSCs) reproduce the main functions of the parental cells and therefore represent the ideal type of EVs for modulating the course of either disease. The aim of this review is to discuss the role of EVs in OA and RA focusing on their potential pathogenic effect and possible therapeutic options. Special attention is given to MSCs and MSC-derived EVs for modulating OA and RA progression with the perspective of developing innovative therapeutic strategies.

show abstract

Section: Mesenchymal Stem Cells and Rheumatic Diseasesmentioning

confidence: 99%

Pathogenic or Therapeutic Extracellular Vesicles in Rheumatic Diseases: Role of Mesenchymal Stem Cell-Derived Vesicles

Cosenza

Ruiz

Maumus

et al. 2017

IJMS

Self Cite

View full text Add to dashboard Cite

show abstract

“…The Mesenchymal and Tissue Stem Cell Committee of the International Society for Cellular Therapy (ISCT) has proposed a minimal set of three criteria to define human MSCs [13] which have been recently updated [14]. Both SVF cells and cultured ASC have shown great promise in various therapeutic fields such as wound healing [15, 16], scleroderma [17, 18], osteoarthritis [19], erectile dysfunction [20], multiple sclerosis [21], and renal insufficiency [22] and numerous clinical trials are being conducted with the use of SVF or ASC (https://clinicaltrials.gov/). …”

Section: Introductionmentioning

confidence: 99%

Evaluation of Three Devices for the Isolation of the Stromal Vascular Fraction from Adipose Tissue and for ASC Culture: A Comparative Study

Rodriguez

Pratta

Abbassi

et al. 2017

Stem Cells International

View full text Add to dashboard Cite

Adipose-derived stem/stromal cells (ASCs) reside in the stromal vascular fraction (SVF) of adipose tissue (AT) and can be easily isolated. However, extraction of the SVF from lipoaspirate is a critical step in generating ASC, and semiautomated devices have been developed to enhance the efficacy and reproducibility of the outcomes and to decrease manipulation and contamination. In this study, we compared the reference method used in our lab for SVF isolation from lipoaspirate, with three medical devices: GID SVF-1™, Puregraft™, and Stem.pras®. Cell yield and their viability were evaluated as well as their phenotype with flow cytometry. Further on, we determined their proliferative potential using population doublings (PD), PD time (PDT), and clonogenicity assay (CFU-F). Finally, we checked their genetic stability using RT-qPCR for TERT mRNA assay and karyotyping as well as their multilineage potential including adipogenic, chondrogenic, and osteogenic differentiation. Our results demonstrate that all the devices allow the production of SVF cells with consistent yield and viability, in less time than the reference method. Expanded cells from the four methods showed no significant differences in terms of phenotype, proliferation capabilities, differentiation abilities, and genetic stability.

show abstract

“…There are very few studies that have shown the therapeutic effect of MSC derived EVs in combating OA. These studies showed that MSC-EVs are capable of cartilage regeneration [17,30]. The use of EVs as a therapeutic agent for treating OA still needs to be investigated further.…”

Section: Cell Based Therapymentioning

confidence: 99%

“…These can be derived from various sources such as bone marrow, adipose tissue, umbilical cord, Wharton's jelly and so on. MSCs are widely studied for OA treatment as it expresses certain enzymes such as growth factors, cytokines and are also capable of exerting anti-inflammatory activity [17,18]. Recently Davatchi et al [19] studied 5 year follow up of three patients of knee OA.…”

Section: Cell Based Therapymentioning

confidence: 99%

Cell Therapy for Osteoarthritis

Thacker

Lin

2017

JSRT

View full text Add to dashboard Cite

Osteoarthritis (OA) also known as degenerative joint disease or degenerative arthritis is the most common chronic condition of the joints. It mainly damages the articular cartilage which results in pain, swelling and stiffness around the joints. It is the leading cause of disability and pain. Current therapeutic strategies are expensive and they are capable of eradicating only the symptoms of OA instead of reversing the damage caused by it. The aim of this review is to introduce the latest stem cell advances as a novel and effective therapeutics for the treatment of OA. One of the most effective stem cell source is mesenchymal stem cells (MSCs) derived from bone marrow as well as from adipose tissues. Other cell sources which have the capability of becoming a novel treatment for OA such as induced pluripotent stem cells (iPSs), embryonic stem cells (ESCs) and extracellular vesicles derived from MSCs have also been highlighted in this review.

show abstract

Therapeutic application of mesenchymal stem cells in osteoarthritis

Cited by 74 publications

References 87 publications

Pathogenic or Therapeutic Extracellular Vesicles in Rheumatic Diseases: Role of Mesenchymal Stem Cell-Derived Vesicles

Pathogenic or Therapeutic Extracellular Vesicles in Rheumatic Diseases: Role of Mesenchymal Stem Cell-Derived Vesicles

Evaluation of Three Devices for the Isolation of the Stromal Vascular Fraction from Adipose Tissue and for ASC Culture: A Comparative Study

Cell Therapy for Osteoarthritis

Contact Info

Product

Resources

About